Exact Sciences (EXAS)

• Market cap: $12.7B
• 1 day: -1.06%
• 5 days: -0.83%
• 1 month: 10.68%
• 3 months: 48.99%
• 6 months: 22.16%
• Year to date: 17.74%
• 1 year: 31.61%
• 5 years: -44.82%
• 10 years: 608.56%
• Sector: Healthcare
• Industry: Diagnostics & Research

About: Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.

Employees: 7,000